Many critiques I've seen were based the premise that FDA approval would force (public and private) insurers to cover Aduhelm. This decision by CMS indicates that such concerns may have been misguided: it's possible to have FDA accelerated approval without forcing taxpayers to cover the treatment cost.

To be clear, it's possible that the blowback around the FDA decision led to CMS's decision, so I'm not critiquing the critiques. Just keeping in mind that this seems like a pretty ideal outcome.